Shares of Orion Oyj (OTCMKTS:ORINY - Get Free Report) hit a new 52-week high during trading on Thursday . The stock traded as high as $33.52 and last traded at $33.52, with a volume of 351 shares changing hands. The stock had previously closed at $33.01.
Analyst Ratings Changes
Separately, Nordea Equity Research lowered shares of Orion Oyj to a "hold" rating in a research report on Tuesday, February 4th.
Get Our Latest Report on ORINY
Orion Oyj Stock Up 4.8%
The stock's 50-day moving average price is $30.19 and its two-hundred day moving average price is $27.15. The company has a current ratio of 2.42, a quick ratio of 1.41 and a debt-to-equity ratio of 0.25. The stock has a market capitalization of $9.91 billion, a P/E ratio of 27.87 and a beta of 0.17.
Orion Oyj (OTCMKTS:ORINY - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The company reported $0.23 earnings per share for the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. The business had revenue of $373.03 million during the quarter. As a group, research analysts expect that Orion Oyj will post 1.18 earnings per share for the current fiscal year.
Orion Oyj Increases Dividend
The firm also recently announced a dividend, which was paid on Tuesday, April 29th. Shareholders of record on Monday, April 7th were given a dividend of $0.4478 per share. The ex-dividend date was Monday, April 7th. This is a positive change from Orion Oyj's previous dividend of $0.24. Orion Oyj's dividend payout ratio (DPR) is currently 24.43%.
About Orion Oyj
(
Get Free Report)
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.
See Also
Before you consider Orion Oyj, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orion Oyj wasn't on the list.
While Orion Oyj currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
